CryoCath Announces Fiscal 2008 First Quart...( http://www MONTREAL Fe...),Health

http://www.cryocath.com Toronto Stock Exchange Symbol: CYT

MONTREAL, Feb. 14 /PRNewswire-FirstCall/ - CryoCath(R) Technologies Inc., the global leader in cryotherapy products to treat cardiac arrhythmias, today announced financial results for the first quarter, ended December 31, 2007.

Selected First Quarter Financial and Operational Highlights:

- EP Revenue for Q1 2008 was $8.7 million or a strong 32.2% increase

over Q1 2007. All regions around the world showed healthy revenue

growth.

- Rapid expansion in the number of active Arctic Front(R) sites in

Europe - from 23 at the end of Q4'07 to 34 sites at the end of Q1. As

well, we see rapid ongoing expansion in the number of installed

consoles worldwide by 33 in Q1 to a total of over 507 consoles world-

wide.

- Explosive sales growth of our flagship product Arctic Front with a 97%

revenue increase over Q1 2007.

- Strong progress in enrollment of patients in our Pivotal STOP AF IDE

Trial, with 210 patients consented as of February 13, 2008. The

program remains firmly on track for April completion of enrollment and

late 2009 FDA approval.

- Gross profit of 51.8% keeps us on track towards achieving our long-

term goal of at least 70% gross margins post launch in the US. Margin

improvements will be driven by the impact of volume increases, mix

improvements, as well as by ongoing improvements in process design.

- Net loss of $6.1 million, an increase of $2.6 million over Q1 2007.

This increase reflects the impact of reduced revenues and volume

following the sale of our surgical portfolio in June 2007. Excluding a

large non-recurring foreign exchange gain in Q1 2007, departmental

spending increased by only 1% versus the prior year, this despite t
'/>"/>